MedTrace Logo

the Clinical Trial of Teicoplanin for Injection

NCT03020901 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100000

Last updated 2017-01-13

No results posted yet for this study

Summary

1. Primary study endpoint Security Effectiveness
2. Secondary study endpoint Extensive use of population characteristics Clinical drug characteristics appropriate crowd characteristics Adverse reactions susceptible population characteristics Reveal rare, new, unanticipated and long-term adverse drug reactions bacterial resistance Explore the advantages of teicoplanin in combination with other antimicrobial agents Explore the opportunistic use of teicoplanin for injection

Conditions

Interventions

DRUG

Teicoplanin for Injection

Use Teicoplanin for Injection

Sponsors & Collaborators

  • Jiangsu Famous Medical Technology Co., Ltd.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-08-31
Completion
2018-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03020901 on ClinicalTrials.gov